Viral B19R Fc Chimera Biotinylated Protein組換え体(リコンビナント)タンパク質 | Recombinant Viral B19R Fc Chimera Biotinylated Protein

R&D Systems社の高品質なViral B19R Fc Chimera Biotinylated Proteinの組換え体タンパク質(Recombinant Viral B19R Fc Chimera Biotinylated Protein)です。

※本製品は研究用です。研究用以外には使用できません。

※バルク包装品も承ります。お気軽にお問合せ下さい。

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

B19R is a 60-65 kDa protein encoded by the Vaccinia virus genome and by the genomes of other orthopoxviruses. Its function represents one of several mechanisms used by these viruses to evade the host immune response (1, 2). It is known as B19R in the Copenhagen strain of Vaccinia and as B18R in the Western Reserve (WR) strain (3). There is a structurally-unrelated, larger Vaccinia protein that is also known as B18R that contains multiple ankyrin-like repeats (4). B19R, however, contains three immunoglobulin-like domains and shows homology to human, mouse, and bovine type I interferon receptors (5). The Wyeth strain of Vaccinia virus encodes a truncated protein that lacks the C-terminal Ig-like domain, and B19R is functionally absent in the Lister strain (6, 7). B19R functions as a decoy receptor for type I interferons (IFN alpha, beta, omega). It binds to type I interferons from multiple species and prevents IFN signaling through its receptors (6-8). B19R binds to the surface of virus infected and uninfected cells where it retains its capacity to bind and neutralize IFN (6, 8). It shields those cells from the antiviral effects of type I interferons, thereby enabling virus replication and pathogenicity (6-8). B19R also limits the effectiveness of IFN alpha produced following TLR activation (9), and it limits adaptive T cell responses (3).